Showing results (101-110 of 139) with videos related to
Sort By:
Pageof 14
Liver Cancer|October 30, 2023
Pembrolizumab as Second-Line Therapy for Advanced Hepatocellular Carcinoma: Longer Term Follow-Up from the Phase 3 KEYNOTE-240 TrialPhilippe Merle, Masatoshi Kudo, Julien Edeline, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 13, 2022
Nivolumab Plus Cabozantinib With or Without Ipilimumab for Advanced Hepatocellular Carcinoma: Results From Cohort 6 of the CheckMate 040 TrialThomas Yau, Vittorina Zagonel, Armando Santoro, et al.Cancer|November 24, 2020
Health-related quality-of-life impact of pembrolizumab versus best supportive care in previously systemically treated patients with advanced hepatocellular carcinoma: KEYNOTE-240Baek-Yeol Ryoo, Philippe Merle, Amit S Kulkarni, et al.Investigational New Drugs|November 10, 2025
A phase 2, open-label, single-arm study evaluating the combination of pembrolizumab, lenvatinib, carboplatin and pemetrexed in patients with metastatic non-small cell lung cancer harbouring targetable genomic alterations who progressed on standard tyrosine kinase inhibitorsHoi Wai Chan, Chris Chun Long Tse, Yu-Chung Li, et al.Liver Cancer|September 26, 2022
Systemic Treatment of Advanced Unresectable Hepatocellular Carcinoma after First-Line Therapy: Expert Recommendations from Hong Kong, Singapore, and TaiwanThomas Yau, David Tai, Stephen Lam Chan, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 3, 2019
Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III TrialRichard S Finn, Baek-Yeol Ryoo, Philippe Merle, et al.ESMO Open|August 28, 2020
Second-line cabozantinib after sorafenib treatment for advanced hepatocellular carcinoma: a subgroup analysis of the phase 3 CELESTIAL trialRobin Kate Kelley, Baek-Yeol Ryoo, Philippe Merle, et al.European Journal of Cancer (Oxford, England : 1990)|April 1, 2022
Updated efficacy and safety of KEYNOTE-224: a phase II study of pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenibMasatoshi Kudo, Richard S Finn, Julien Edeline, et al.Lancet (London, England)|April 19, 2023
Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trialRobin Kate Kelley, Makoto Ueno, Changhoon Yoo, et al.Journal of Hepatology|March 28, 2025
Health-related quality of life in participants with advanced biliary tract cancer from the randomized phase III KEYNOTE-966 studyChanghoon Yoo, Makoto Ueno, Heinz-Josef Klümpen, et al.Pageof 14